Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan

被引：0
|
作者：
Hsia, T. [1 ]
Chang, G. [2 ]
Chen, Y. [3 ]
Lin, M. [4 ]
Su, W. [5 ]
Tsai, C. [3 ,6 ]
Tsai, C. [3 ,6 ]
Yang, L. [6 ]
机构：
[1] China Med Univ Hosp, Dept Pulm Med, Taichung, Taiwan
[2] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[3] Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[4] Chang Guang Mem Hosp, Dept Pulm & Crit Care Med, Kaohsiung, Taiwan
[5] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[6] Roche Prod Ltd, Dept Pharma, Taipei, Taiwan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71386-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6558
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [1] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [2] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [3] GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
    Yang, M.
    Tan, E. C.
    Chen, Y.
    VALUE IN HEALTH, 2016, 19 (07) : A885 - A885
  • [4] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [5] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    LUNG CANCER, 2009, 64 : S13 - S13
  • [6] Advanced non-small cell lung cancer. Maintenance and second-line treatment
    Schuette, W.
    Nagel, S.
    Haak, G.
    Steinert, M.
    PNEUMOLOGE, 2012, 9 (01): : 43 - 48
  • [7] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [8] Second-line treatment for advanced non-small cell lung cancer:: A systematic review
    Barlési, F
    Jacot, W
    Astoul, P
    Pujol, JL
    LUNG CANCER, 2006, 51 (02) : 159 - 172
  • [9] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [10] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
12345